TRANSFUSION SCIENCE ARTICLES
Annual SHOT Report 2024: laboratories in need of a lifeline
In its 2024 annual report, the Serious Hazards of Transfusion (SHOT) scheme shows evidence of a particularly challenging year for staff working in transfusion laboratories.
The SHOT Report 2023: Can opportunity follow learning from adversity?
The Serious Hazards of Transfusion (SHOT) scheme has recently published its Annual Report, collecting and analysing information on serious adverse events in blood transfusion within the UK. SHOT Laboratory Incident Specialist Victoria Tuckley presents a summary of its key points.
Appropriate blood provision for sickle cell disease patients in Northern Ireland
The appropriate selection of blood for transfusion in the ongoing treatment of patients with sickle cell disease is of vital importance. Here, Hannah Caldwell examines the role of sickle solubility testing and molecular genotyping in the care of SCD patients in Northern Ireland.
All together now: Summary of the 2022 Annual SHOT Report
The 2022 Annual Report from the Serious Hazards of Transfusion (SHOT) scheme has been published recently, once again collecting and analysing anonymised information on serious adverse events and reactions in blood transfusion from all healthcare organisations. Here SHOT Laboratory Incident Specialist Victoria Tuckley summarises its key points and recommendations.
Striving to improve transfusion safety: The 2021 SHOT Report
Nicola Swarbrick, Laboratory Incident Specialist at the Serious Hazards of Transfusion scheme, presents the key findings and recommendations from its 2021 report, which also marks 25 years since it was created to oversee and review haemovigilance reporting.
Incident investigation in blood transfusion practice: a review and update
In this article, Serious Hazards of Transfusion laboratory incident specialist Nicola Swarbrick focuses on a specific area of transfusion science haemovigilance practice – incident investigation – that was the topic of a SHOT webinar held last year.
Latest Issues
Epredia was established in July 2019 through the acquisition by PHC Group of the Anatomical Pathology division of Thermo Fisher Scientific. Our name has changed, however as a standalone business our mission remains the same: to improve lives by enhancing cancer diagnostics.
We are powered by the quality brands you know and trust, such as...
UK NEQAS webinar: Introduction to Cellular Components, Tissue Morphology and Tissue Recognition
Online
3-4 March, 2026
Cell & Gene Therapy 2026
Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, CB10 1RQ
9-10 March, 2026
UK NEQAS webinar: Specialist Demonstration of Lipids, Pigments, Minerals, and Infections
Online
10-11 March, 2026
USCAP 115th Annual Meeting
Henry B. González Convention Center, San Antonio, Texas, USA
21-26 March, 2026
Analytica 2026
Messe München, Munich, Germany
24-27 March, 2026